

Tel. : (91 832) 6714444 E-mail : gkbophthalmics@gkb.net Website : www.qkb.net

GKB/ STK- EXCH August 13, 2024

To,
The Listing Department
BSE Limited
Phiroze Jeejubhoy Towers, Dalal Street
Mumbai - 400 001

Dear Sir,

Ref: Scrip Code No.: 533212

Sub: Statement of deviation(s) or variation(s) under Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – June 30, 2024

Pursuant to Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD1/162/2019, dated December 24, 2019, we would like to inform you that the Audit Committee in its meeting held on August 13 2024, has reviewed the utilization of funds which were raised by means of preferential allotment and noted that during the quarter ended June 30, 2024 the Company has fully utilized the remaining balance funds for purposes as stated in the objects of the issue.

Enclosed please find the Statement as per the format, giving details of the same.

Kindly take the information on records.

Thanking you

Yours faithfully,

For GKB Ophthalmics Limited

Pooja Bicholkar

Company Secretary



## Statement of Deviation / Variation in utilisation of funds raised

Name of listed entity	GKB Ophthalmics Limited			
Mode of Fund Raising	Public Issues / Rights Issues / Preferential Issues / QIP / Others			
Date of Raising Funds	July 27, 2018 and January 22, 2020			
Amount Raised	Equity Shares – Rs. 7,54,85,000			
	Warrants – Rs. 2,90,62,500 Warrants - Rs. 4,65,00,000 (75% of balance warrant money received on or before January 21, 2020, with respect to 4,00,000 warrants)			
Report filed for Quarter ended	June 30, 2024			
Monitoring Agency	applicable / not applicable			
Monitoring Agency Name, if applicable	Yes / No			
Is there a Deviation / Variation in use of funds raised	There was no Deviation or Variation in the utilization of			
	funds during the quarter ended June 30, 2024.			
If yes, whether the same is pursuant to change in terms of a contract				
or objects, which was approved by the shareholders				
If Yes, Date of shareholder Approval				
Explanation for the Deviation / Variation				
Comments of the Audit Committee after review	The audit committee noted that during the quarter ended June 30, 2024 the Company has fully utilized the remaining balance funds for purposes as stated in the objects of the issue.			
Comments of the auditors, if any				

Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised	Amount of Deviation/Variation for the quarter according to applicable object	Remarks, if any
The Company will utilize the funds raised through preferential ssue to scale up the operations in the present business, to fund the future growth plans of the Company both organically or	N.A	15.10 Crores	N.A	15.10 Crores	N.A	N.A
inorganically, also to meet long term capital requirements of the Company and other general corporate purpose.	estric		upplicately not a  Yes No  There use not is  Jambani mag by	egginggeler Marration of Assacratic Grigolof or et al. Lorent	in the arthization of	

Deviation or variation could mean:

(a) Deviation in the objects or purposes for which the funds have been raised or

(b) Deviation in the amount of funds actually utilized as against what was originally disclosed or

(c) Change in terms of a contract referred to in the fund raising document i.e. prospectus, letter of offer, etc

Pooja Bicholkar

Company Secretary